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Metabolomics is an emerging field in analytical biochemistry and can
be regarded as the end point of the “omics” cascade. Whereas
genomics deals with the analysis of the complete genome in order to
understand the function of single genes, the majority of functional
genomics studies are currently based on the analysis of gene expres-
sion (transcriptomics) and comprehensive protein analysis (pro-
teomics). As we are amassing knowledge of the genome, the
transcriptome, and the proteome, we have largely forgotten the
metabolome. However, changes in the metabolome are the ultimate
answer of an organism to genetic alterations, disease, or environmen-
tal influences. The metabolome is therefore most predictive of
phenotype (Fiehn 2002; Weckwerth 2003). Consequently, the com-
prehensive and quantitative study of metabolites, or metabolomics, is
a desirable tool for either diagnosing disease or studying the effects of
toxicants on phenotype.
One of course wonders why metabolomics has lagged behind
other “omics” technologies. Possibly this is because the number of
metabolites varies dramatically based on how they are counted.
Investigators also debate about what compounds are considered
metabolites; for example, should vitamins or smaller peptides be
included? According to a simple and widely used definition, a
metabolite is any substance involved in metabolism either as a
product of metabolism or necessary for metabolism. In any case
3,000 major metabolites seem a reasonable number. If we attempt
a global and quantitative evaluation, the technology involved is
daunting because the physical properties of the compounds are so
divergent and they vary dramatically in concentration. Moreover,
the metabolome is a dynamic system subjected to significant
environmental influences, for example, temporal or dietary. 
It is difficult to envision a single platform being developed in
the near future that is able to analyze quantitatively all metabolites
simultaneously. Thus with all metabolites as our goal, the techno-
logical hurdle seems to be the limiting step. At the other extreme,
metabolomics can be seen as metabolite profiling or “just” analyti-
cal chemistry. So it is nothing new, simply multi-analyte chemistry
that biochemists have been doing for decades. Of course
metabolomics is simultaneously both and neither of these.
Although an “omics” or global view of metabolism is a goal, by no
means is universal coverage of all metabolites required for tremen-
dous biological insight. Also whether we work on complete cover-
age of a single metabolic pathway or on a more global approach to
examine multiple metabolites, such multi-analyte analysis is by no
means trivial. Nevertheless, successful implementation of
metabolomics requires analytical instrumentation that offers high
throughput, resolution, reproducibility, and sensitivity, and only
an assembly of different analytical platforms will currently provide
maximum coverage of the metabolome. To date, metabolomics-
type studies rely primarily on nuclear magnetic resonance (NMR)
or mass spectrometry coupled to chromatography. 
Currently, two complementary approaches are used for
metabolomic investigations. In one approach—metabolic profil-
ing—quantitative analytical methods are developed for metabolites
in a pathway or for a class of compounds. This approach produces
independent information that can be interpreted in terms of
known biochemical pathways and physiological interactions. These
data represent an independent legacy database since they are quan-
titative. The disadvantage is that the system is not a universal or
“omics” approach.
However, the tremen-
dous advances in
technology over the
past years allow the
constant expansion of
the number of analytes quantified simultaneously. Technologically, we
are at a point where it is often as simple to measure many compounds
as to measure one. If we take one step further and assemble a suite of
quantitative methods analyzing key metabolites from different bio-
chemical pathways, we can transform metabolic profiling into
metabolomics.
The second approach is metabolic fingerprinting. In such
metabolomic investigations, the intention is not to identify each
observed compound but to compare patterns or fingerprints of
metabolites that change in response to disease or toxin exposure.
Comparison of fingerprints, often NMR or mass spectra or chro-
matograms, is performed using statistical tools such as hierarchical
cluster analysis or principal component analysis. If these types of
analyse results in sample segregation into unique metabolic clus-
ters, further efforts can be made to elucidate the discriminating
compounds and subsequently to evaluate these monocytes as
potential biomarkers. Being semiquantitative and simultaneously
applicable to a wide range of metabolites—this is a true “omics”
approach. Such methods are attractive, as they allow investigators
to cast a wide net both generating and testing hypotheses.
However, the nature of the data makes the observations instru-
ment/platform dependent. The implementation of NMR-based
metabolic fingerprinting has marked the beginning of a
metabolomics approach as a tool in biochemistry and has proven to
be a powerful technique (Nicholson et al. 2002). However, it will
only detect high abundance metabolites. Complementary to NMR,
mass spectrometry–based tools will provide coverage for metabolic
fingerprinting in a lower concentration range, and their use is
increasing steadily (Plumb et al. 2003). 
The combination of metabolic profiling and fingerprinting will
lead to the realization of metabolomics. In one approach, changes
in fingerprints correlating to metabolite profiles will be linked to a
physiological state, without exact knowledge of fingerprint compo-
nents. In another approach, discriminating compounds identified
in fingerprints will become the focus for quantitative metabolite
analyses. Therefore, metabolomics will contribute to our biological
understanding both in a mechanistic as well as a predictive
manner. However, it could also assist us in improving human
health and may be among the first of the “omics” technologies to
reach the clinic. Through multiple metabolomics projects, a pow-
erful list of likely markers of variations in health can evolve
(Watkins and German 2002). Analyzing this set of biomarkers in a
single high throughput assay will provide the clinician with a
powerful diagnostic tool. 
In genomics and transcriptomics we saw economies of scale as
institutional support developed generating infrastructure behind
the technologies. Similar support will be necessary to advance
metabolomics. For example, a centralized effort to provide iso-
topic-labeled standards for a wide range of metabolites would
tremendously accelerate work in metabolomics as would the devel-
opment of an integrated pathway map to aid in data interpretation.
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flux through pathways. 
Although metabolomics is still in an early evolutionary stage,
we can expect to see exciting new developments in the near future.
As more quantitative metabolomic databases evolve, we can inte-
grate them with data sets from the other “omics” technologies to
enhance the data value and provide greater biological insight than
any one “omics” technique alone can offer. 
Katja Dettmer 
Bruce D. Hammock
Cancer Research Center
University of California, Davis
Davis, California
E-mail: bdhammock@ucdavis.edu
Katja Dettmer is a postdoctoral researcher in professor Bruce
Hammock’s laboratory at the University of California, Davis. She is
conducting research in the field of metabolomics, focusing on the devel-
opment of mass spectrometry–based tools for metabolic fingerprinting
in biofluids as well as metabolic profiling methods.
Bruce Hammock is a Distinguished Professor of Entomology and a sci-
entist in the Cancer Research Center at the University of California,
Davis. He directs an analytical–metabolomics laboratory that pio-
neered the use of immunochemical diagnostics in the environmental
field. His research interests include development of recombinant viral
pesticides, mammalian xenobiotic metabolism, environmental chem-
istry, and biosensor development.
REFERENCES
Fiehn O. 2002. Metabolomics—the link between genotypes and phenotypes. Plant Mol
Biol 48:155–171.
Plumb RS, Stumpf CL, Granger JH, Castro-Perez J, Haselden JN, Dear GJ. 2003. Use of
liquid chromatography/time-of-flight mass spectrometry and multivariate statistical
analysis shows promise for the detection of drug metabolites in biological fluids.
Rapid Commun Mass Spectrom 17:2632–2638.
Nicholson JK, Connelly J, Lindon JC, Holmes E. 2002. Metabonomics: a platform for
studying drug toxicity and gene function. Nat Rev Drug Discov 1:153–161. 
Watkins SM, German J B. 2002. Toward the implementation of metabolomic assess-
ments of human health and nutrition. Curr Opin Biotechnol 13:512–516.
Weckwerth W. 2003. Metabolomics in systems biology. Annu Rev Plant Biol 54:669–689.
Environmental Health Perspectives • VOLUME 112 | NUMBER 7 | May 2004 A 397
Guest Editorial
Metabolomics can be regarded as the end point of the “omics” cascade.